Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00464113
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia (Ph+ ALL)
Study Start Date
Primary Completion Date
Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The subject has a confirmed pathologic diagnosis as evidenced by the presence of the BCR-Abl translocation [t(9;22)] by fluorescence in situ hybridization (FISH), cytogenetics, or quantitative polymerase chain reaction (QPCR) of one of the following:
Chronic phase (CP)
Accelerated phase (AP)
Blast phase (BP) OR
The subject has one of the following:
Known T315I Abl mutation
Known resistance to or intolerance of imatinib and dasatinib
At least one prior anti-leukemia therapy, including, but not limited to, interferon, imatinib, or dasatinib
The subject is at least 18 years old.
The subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
The subject has adequate organ function.
The subject is capable of understanding and complying with the protocol and has signed the informed consent document.
Sexually active subjects must use an accepted method of contraception during the course of the study.
Female subjects of childbearing potential must have a negative pregnancy test at enrollment.
The subject has received interferon, imatinib, or dasatinib within 7 days of the first dose of XL228.
The subject has received an investigational agent or radiotherapy within 28 days of the first dose of XL228.
The subject has received immunosuppressive therapy (eg, cyclosporine, steroids, tacrolimus for graft-versus-host disease [GVHD]) within 28 days prior to the first dose of XL228.
The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade ≤1 from toxicities related to peripheral stem cell or bone marrow transplant.
The subject has not recovered to CTCAE v3.0 Grade ≤1 from adverse events (AEs) due to investigational drugs or other medications.
The subject has known allergy or hypersensitivity to any component of the investigational drug product.
The subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, diabetes, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
The subject is pregnant or breastfeeding.
The subject is known to be positive for the human immunodeficiency virus (HIV).
The subject has an inability or unwillingness to abide by the study protocol or cooperate fully with the investigator or designee.